Navigation Links
BioCryst to Present at the 11th Annual BIO CEO & Investor Conference
Date:2/2/2009

erformance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that our belief that many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular injection may not be correct, that HHS and the Food & Drug Administration (FDA) may not agree with our analysis, that HHS may further condition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the peramivir program may not be successful, that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future preclinical and clinical development may not have positive results, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not be able to retain its current pharmaceutical and biotechnology partners for further deve
'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. BioCryst Pharmaceuticals to Announce Fourth Quarter and Year End 2008 Financial Results on February 6, 2009
2. BioCryst to Present at the Rodman and Renshaw 10th Annual Healthcare Conference
3. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
4. BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008
5. BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007
6. Interleukin Genetics to Present at G-2 Reports Molecular Diagnostic Conference
7. Prescription Drugs: Good Medicine - Bad Behavior; Science Matters Program Explores the Rise in Prescription Drug Abuse Presented by the California Science Center
8. Inverness Medical Innovations to Present at the 2009 UBS Global Healthcare Services Conference on February 10, 2009
9. eResearchTechnology, Inc. to Present at the UBS Global Healthcare Services Conference on February 10, 2009
10. Triple-S Management Corporation to Present at UBS Global Healthcare Services Conference
11. International Medical Interpreter Association Appoints IMIA State Representatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 (HealthDay News) -- It can happen in an instant: ... or computer monitor and gets critically injured when the furniture ... child should look around their homes and imagine what could ... it is better than it becoming a reality," Dr. Alex ... in a college news release. Between 2009 and 2011, ...
(Date:7/30/2014)... SF Cable, distributor of the highest quality ... the internet with guaranteed customer satisfaction announces the availability ... colors. These lightning cords are MFI certified to meet ... SF Cable Lightning to USB Cables feature ... charging and syncing. Compatible with the iPhone 5S/5C/5 plus ...
(Date:7/30/2014)... New York, New York (PRWEB) July 30, 2014 ... died from uncontrollable brain bleeding has filed a Xarelto ... caused by the blood thinner, Bernstein Liebhard LLP reports. ... District Court for the District of Vermont on July ... 10 days when he suffered an irreversible brain bleed ...
(Date:7/30/2014)... Visitors to our region recognize how special it ... protection. Bob Kiesendahl, one of the owners of Woodloch ... Conservancy for donations collected through participation in the Green ... fast, as visitors welcome the opportunity to invest in ... The Kiesendahl family has owned Woodloch Resort for multiple ...
(Date:7/30/2014)... 2014 (HealthDay News) -- Some obese people have a ... centers in their brains when they see food, researchers ... mutation triggers feelings of pleasure and gratification at the ... strategies designed to prevent overeating, the scientists suggested. ... is typically caused by a combination of overeating, ...
Breaking Medicine News(10 mins):Health News:Tip-Over Furniture Can Kill Kids 2Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2Health News:Gene Mutation May Make Food More Tempting 2
... Healthcare Pharmacy, one of,the nation,s largest independent specialty pharmacy ... Companies for 2008." This is the fourth,consecutive year that ... "We are pleased by this recognition," said Mark ... employees we have experienced,continued growth within our industry." , ...
... in the 12th January issue of Archives of ... blood pressure and outdoor temperature in a large sample ... that, during periods of extreme temperatures, careful monitoring of ... the consequences of blood pressure variations in the elderly". ...
... National Lung Cancer Partnership is pleased to announce I-Ching ... of the 2009 Career Development Award. , The $80,000 ... to develop their careers in lung cancer research. ... a protein that binds to specific parts of DNA and ...
... To increase access to,healthcare services and improve health outcomes ... (ICTPH) has partnered with the, University of Pennsylvania, School ... of nurse-managed Rural Micro Health Centres (RMHC) in Tamil,Nadu, ... stage of the partnership, which was signed in January,and ...
... kids from birth to age 21 , , FRIDAY, Jan. 16 ... study that aims to track tens of thousands of children ... at understanding of how genes and environment interact to affect ... Congress in 2000, is expected to uncover important health information ...
... 16 It,s no secret that the,economic landscape ... eat. But, are you,willing to sacrifice your well-being ... other consumers in a recent nationwide study conducted ... convenient and,all-natural snacks. There are many healthy snacks ...
Cached Medicine News:Health News:Seasonal variation in blood pressure 2Health News:ICTPH Partners With University of Pennsylvania, School of Nursing to Enhance Rural Health 2Health News:ICTPH Partners With University of Pennsylvania, School of Nursing to Enhance Rural Health 3Health News:National Childrens Study Begins Recruiting 2Health News:Americans Continue Eating Nutritious and Convenient Snacks Despite Tough Economic Times 2Health News:Americans Continue Eating Nutritious and Convenient Snacks Despite Tough Economic Times 3
(Date:7/30/2014)... PITTSBURGH , July 30, 2014   ... Markets Groups Inc.: OTC Pink: UPZS), a Delaware ... a distribution agreement with Larasan Pharmaceutical Corporation ("Larasan"), a ... products.  According to the agreement, US-based Larasan will ... gourmet 6" frozen pizza through Larasan,s vast distribution ...
(Date:7/30/2014)... and PARIS , July 30, ... ) and Sanofi (EURONEXT: SAN and NYSE: ... ODYSSEY trials of alirocumab in people with hypercholesterolemia met ... from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 ... an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin ...
(Date:7/30/2014)... PHILADELPHIA , July 30, 2014  Packaging Coordinators, ... a definitive agreement to acquire Penn Pharmaceutical Services Limited ... Wales in the United Kingdom ... New Hope, Pennsylvania and Tokyo ... manufacturing services, including Clinical and Commercial dosage form manufacturing, ...
Breaking Medicine Technology:Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5
... /PRNewswire-Asia/ -- China Kanghui Holdings (NYSE: KH ) ... marketer of orthopedic implants in China, today announced that the ... August 16, 2011, before the market opens. Kanghui ... August 16, 2011 to discuss second quarter results and answer ...
... ATLANTA, July 28, 2011 Data presented this week at ... many people have low vitamin D levels and that testing ... to published data from the Third National Health and Nutrition ... only 23 percent of Americans have vitamin D levels over ...
Cached Medicine Technology:China Kanghui Holdings to Report Second Quarter 2011 Financial Results on August 16, 2011 2Data Presented at American Association for Clinical Chemistry Meeting Show Many Americans May Have Low Vitamin D Levels 2Data Presented at American Association for Clinical Chemistry Meeting Show Many Americans May Have Low Vitamin D Levels 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: